Statement re share price, update on EpiSwitch PSE

Oxford BioDynamics PLC

03 December 2025

 

3 December 2025 

Oxford BioDynamics Plc

("OBD" or the "Company" and, together with its subsidiaries, the "Group")

Statement re share price movement, update on EpiSwitch PSE

The Board of Oxford BioDynamics Plc (AIM: OBD, the Company), a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on its EpiSwitch® 3D genomics platform, notes the recent movement in the Company's share price following the publication on 28 November of the UK National Screening Committee's (NSC) draft recommendation in respect of prostate cancer screening.

The NSC's draft recommendation has no direct impact on OBD or the Group's EpiSwitch PSE test. PSE test sales in the US and to private healthcare in the UK have continued to increase, with six successive record months reported from June to November 2025.

-Ends-

For further details please contact:

Oxford BioDynamics Plc	Tel: [phone]
Iain Ross, Executive Chairman Paul Stockdale, CFO
Shore Capital - Nominated Adviser and Broker	Tel: [phone]
Stephane Auton / Lucy Bowden
OAK Securities - Joint Broker	Tel: [phone]
Matthew Clarke / Tim Dainton / Calvin Man
Camarco - Financial PR	Tel: [phone]
Marc Cohen / Tilly Butcher / Fergus Young	[e-mail]

Notes to Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is an international biotechnology company, advancing personalized healthcare by developing and commercializing precision clinical diagnostic tests for life-changing diseases.

Currently OBD has two commercially available products: the EpiSwitch® PSE (EpiSwitch Prostate Screening test) and EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer. CiRT is a highly accurate (85%) predictive response test to immuno-oncology checkpoint inhibitor treatments.

The tests are based on OBD's proprietary 3D genomic biomarker platform, EpiSwitch® which enables screening, evaluation, validation and monitoring of biomarkers to diagnose patients or determine how individuals might respond to a disease or treatment.

OBD's clinical smart tests have the potential to be used across a broader range of indications, and new tests are being developed in the areas of oncology, neurology, inflammation, hepatology and animal health.

The Group's headquarters and UK laboratories are in Oxford, UK. Its US operations and clinical laboratory are in Maryland, USA, along with a reference laboratory in Penang, Malaysia.

OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more information, please visit the Company's website, www.oxfordbiodynamics.com,  X (@OxBioDynamics) or LinkedIn.

 

END